Drug discovery requires efficient screening of large molecular libraries to identify promising therapeutic candidates. This work presents a hybrid quantum–classical framework for DPP-4 inhibitor screening using a curated ChEMBL dataset of 3972 molecules. Classical SVR and Random Forest models are first used for broad candidate screening, from which the top 50 molecules are selected for quantum refinement using Quantum Support Vector Regression (QSVR) and a Quantum Kernel Ensemble (QKE). PCA-reduced molecular descriptors are encoded into a quantum feature space and evaluated using fidelity-based quantum kernels, while XGBoost, LightGBM, and MLP Regression are included as additional comparative baselines. Experimental results show that Random Forest achieves the best classical baseline performance with MAE = 0.7735, RMSE = 1.0655, and R2= 0.3625, while QKE achieves MAE = 0.5642, RMSE = 0.7494, and R2= 0.5369 during quantum refinement. The QSVR-selected molecule CHEMBL2063040 exhibits IC50= 0.3 nM with docking affinity of −4.258 kcal/mol, whereas the QKE-selected molecule CHEMBL2069852 exhibits IC50= 91.5 nM and stronger docking affinity of −11.68 kcal/mol. These results support quantum-kernel learning as a focused refinement mechanism in hybrid molecular screening.
Drug discovery requires efficient screening of large molecular libraries to identify promising therapeutic candidates. This work presents a hybrid quantum–classical framework for DPP-4 inhibitor screening using a curated ChEMBL dataset of 3972 molecules. Classical SVR and Random Forest models are first used for broad candidate screening, from which the top 50 molecules are selected for quantum refinement using Quantum Support Vector Regression (QSVR) and a Quantum Kernel Ensemble (QKE). PCA-reduced molecular descriptors are encoded into a quantum feature space and evaluated using fidelity-based quantum kernels, while XGBoost, LightGBM, and MLP Regression are included as additional comparative baselines. Experimental results show that Random Forest achieves the best classical baseline performance with MAE = 0.7735, RMSE = 1.0655, and R2= 0.3625, while QKE achieves MAE = 0.5642, RMSE = 0.7494, and R2= 0.5369 during quantum refinement. The QSVR-selected molecule CHEMBL2063040 exhibits IC50= 0.3 nM with docking affinity of −4.258 kcal/mol, whereas the QKE-selected molecule CHEMBL2069852 exhibits IC50= 91.5 nM and stronger docking affinity of −11.68 kcal/mol. These results support quantum-kernel learning as a focused refinement mechanism in hybrid molecular screening.
Predicting drug-target binding affinity with limited training data remains a central challenge in computational drug discovery. We introduce a hybrid quantum-classical framework combining molecular descriptors with variational quantum circuits for interpretable binding affinity prediction. Seven physicochemical descriptors (MW, logP, TPSA, HBD/HBA, rotatable bonds, aromatic rings) were encoded into 6-qubit variational circuits using parameterized rotations and controlled-Z entanglement. Quantum kernels were extracted and used for regression on 1,200 BindingDB molecules across kinase, GPCR, and protease targets, with external validation on 300 ChEMBL compounds. Performance was compared against SVR, random forest, gradient boosting, and neural network baselines using 100-fold bootstrap validation. Variational quantum regression achieved MSE = 0.056 ± 0.009, outperforming SVR by 32% (0.082 ± 0.013), RF by 28%, and GBM by 24%. Quantum advantage was most significant in low-data regimes (n < 500), where VQR maintained R2 > 0.85 versus R2 < 0.72 for classical methods. External validation confirmed generalization (R2 = 0.83). Our Explainable Quantum Pharmacology framework revealed TPSA and logP as dominant predictive features through gradientbased sensitivity analysis, aligning with established medicinal chemistry principles. Quantum kernels provide measurable, chemically interpretable improvements for molecular property prediction in data-limited scenarios. This work demonstrates practical quantum advantage for early-stage drug discovery applications on near-term quantum hardware.
The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.
Recent advances in quantum machine learning (QML) have opened new pathways for accelerating early-stage drug discovery through molecular representation in Hilbert space [1]–[3]. In this work, we present a hybrid quantum–classical framework that integrates quantum kernel estimation and variational quantum neural networks (QNNs) for ligand–target binding prediction [4], [5].A synthetic dataset reflecting the statistical behavior of the BindingDB database [6] was constructed to evaluate quantum descriptors and kernel performance under controlled conditions. The proposed quantum feature maps translate seven key molecular descriptors—molecular weight (MW), logP, hydrogen bond donors (HBD), acceptors (HBA), rotatable bonds (RB), aromatic rings (AR), and topological polar surface area (TPSA)—into entangled qubit states [7], [8].Comparative analyses with classical baselines (SVR, Random Forest, and deep neural networks) revealed that quantum embeddings achieve competitive predictive accuracy (RMSE ≈ 0.06) with improved stability under bootstrap resampling [9]. Quantum kernel alignment and sensitivity studies demonstrated that aromaticity and polarity jointly determine the representational power of QML models [10].Beyond performance, we emphasize Explainable Quantum Pharmacology (EQP)—a paradigm in which interpretability, reproducibility, and physicochemical causality are as essential as accuracy [11].Our findings establish a reproducible, interpretable, and computationally efficient foundation for hybrid QML pipelines in molecular modeling, paving the way for next-generation AI-driven drug discovery.
Quantitative Structure-Activity Relationship (QSAR) modeling is a cornerstone of computational drug discovery. This research demonstrates the successful application of a Quantum Multiple Kernel Learning (QMKL) framework to enhance QSAR classification, showing a notable performance improvement over classical methods. We apply this methodology to a dataset for identifying DYRK1A kinase inhibitors. The workflow involves converting SMILES representations into numerical molecular descriptors, reducing dimensionality via Principal Component Analysis (PCA), and employing a Support Vector Machine (SVM) trained on an optimized combination of multiple quantum and classical kernels. By benchmarking the QMKL-SVM against a classical Gradient Boosting model, we show that the quantumenhanced approach achieves a superior AUC score, highlighting its potential to provide a quantum advantage in challenging cheminformatics classification tasks.
Recent advances in quantum machine learning (QML) offer new opportunities for chemical property prediction, yet their practical performance relative to established classical models remains poorly characterized on real-world datasets. Building on our previous benchmark of classical and deep learning models for collision cross-section (CCS) predictions, we present an empirical comparison of quantum kernel regression (QKR) and a variational quantum regressor (VQR) against classical machine learning (CML) techniques, including Random Forest (RF), support vector regression (SVR), Lasso, and a Voting Regressor (VR) ensemble. Using an aquatic dissolved organic matter (DOM) dataset with five molecular descriptors and five chemical classes, we systematically investigate QKR feature map repetitions and classical readout kernels, as well as VQR circuit depths and optimizer choices, to identify performance-optimal QML configurations. Regression performance is evaluated using the mean absolute error (MAE), root mean square error (RMSE), and coefficient of determination (R2) across training-set sizes up to 600 molecules per class. Overall, RF and Lasso deliver the most robust CCS predictions, achieving R2 ≥ 0.9 for lignins, carbohydrates, lipids, and proteins. Meanwhile, the optimized QKR architecture exhibits substantial gains as data increase and achieves competitive performance on chemically homogeneous subsets such as carbohydrates and lipids. In contrast, the VQR ansatz remains consistently weaker than both QKR and the classical baselines across all classes and data sizes. The results highlight the strong influence of dataset size, feature representation, and molecular heterogeneity on QML performance while also identifying conditions under which quantum methods may become competitive in future studies.
Classical machine learning models and quantum kernel methods often struggle to capture quantum-coherent molecular features under the constraints of noisy intermediate-scale quantum (NISQ) hardware, limiting both predictive accuracy and scalability. This paper introduces the Molecular Quantum Particle Algorithm (MQPA), a hybrid quantum–classical framework designed to achieve chemically accurate property prediction by integrating handcrafted molecular descriptors with parameterized quantum circuits. Molecular inputs, expressed as SMILES strings, are processed via RDKit and encoded through angle-based quantum gates with entangling layers in Qiskit [1]. Quantum parameters are optimized using simultaneous perturbation stochastic approximation (SPSA) [2], while classical regression layers leverage Adam [3] with Low-Rank Adaptation (LoRA) fine-tuning [4]. Across 38 systematically varied subsets of the QM9 benchmark [5,6], MQPA achieves a mean absolute error (MAE) of 0.03 kcal/mol, outperforming both deep learning and quantum kernel baselines by 41% and surpassing the chemical accuracy threshold of 0.1 kcal/mol [7–9]. Extensive cross-platform benchmarking—including IBM Quantum, Qiskit Aer, and NVIDIA H100 clusters—demonstrates strong reproducibility, with inter-backend MAE variance below 3%. Positioned as a scalable and hardware-aware solution, MQPA offers practical advantages for quantum-enhanced molecular property prediction across applications in quantum chemistry, drug discovery, materials design, and environmental modeling.